NASH and NAFL: it is not only about liver but it is a complex inter-organ crosstalk in which adipose tissue dysfunction is an important driver of the disease. × Prof Jordi Gracia-Sancho, Barcelona, discusses the need to develop new therapeutic approaches that target more than one molecular pathway for chronic liver disease. × Prof Roden highlights the sessions dedicated to obesity and the metabolic syndrom held during the Liver meeting 2019 in Boston × Prof G. Szabo reviews the learnings about alcohol consumption and liver disease that were presented during the Liver meeting 2019 in Boston. × Prof Jean-François Dufour highlights why the Liver meeting 2019 in Boston is relevant for NASH investigators with presentations of new modes of action and non-invasive biomarkers. × <span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span> Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting. × Prof Abdelmalek shares her perspectives about the highlights of the Liver meeting in Boston. She sees a lot of hope in new clinical trials and new biomarkers. × Prof Cusi sheds light on the new exciting information made public at the Liver meeting in Boston. ×
